Dravet Syndrome

These documents provide a comprehensive look at Dravet syndrome, a severe genetic epilepsy primarily caused by SCN1A mutations that trigger frequent, drug-resistant seizures and developmental delays. Current research highlights a shift toward disease-modifying therapies, including gene-targeted treatments and new medications like EPX-100 and relutrigine, which aim to address the condition’s root cause. Beyond pharmaceutical intervention, the texts explore the effectiveness of the ketogenic diet in reducing seizure frequency and improving cognitive outcomes. Managing the disorder requires a holistic approach that includes caregiver support, seizure tracking, and specialized education to handle common comorbidities like sleep and digestive issues. As patients age, the sources emphasize the critical need for healthcare transition planning, beginning in early adolescence to secure legal guardianship and adult medical care. International foundations further offer financial grants and community networks to help families navigate the lifelong complexities of this rare neurological condition.